Connect with us

Technology

CLERIVY Brings a K-Beauty Take on Pimple Patches to Amazon.com

Published

on

CLERIVY’s U.S. debut includes a hydrocolloid patch and a water-soluble microdart patch featuring niacinamide, tranexamic acid and a vitamin C derivative. A separate OTC acne patch with 2% salicylic acid is scheduled for release in October 2026.

SEOUL, South Korea, Aug. 25, 2026 /PRNewswire/ — Korean skincare brand CLERIVY, founded by Guhada Co., Ltd., announced its U.S. debut on Amazon.com today with two cosmetic patches now available: the Hydrocolloid Pimple Patch and the Microdart Spot Patch.

Its third product, the Microdart Acne Patch, will be available in October 2026. It is listed with the FDA as an OTC monograph drug for acne and contains 2% salicylic acid as its sole active ingredient. Its full Drug Facts label has been public on DailyMed since August 12, 2026.

CLERIVY’s U.S. distribution and marketing are led by Kglowing, Guhada’s global accelerator platform, which has supported the overseas expansion of approximately 30 K-beauty brands.

Two Patch Formats for Different Stages

The Microdart Spot Patch is designed for the kind of bump you can feel before you can see it. Its water-soluble microdarts contain 7% niacinamide, 3% tranexamic acid and 2.7% sodium ascorbyl phosphate, a vitamin C derivative used as a cosmetic antioxidant. The formula also includes less than 0.5% salicylic acid for cosmetic purposes only. Niacinamide and tranexamic acid are familiar ingredients in tone-focused skincare, while panthenol and madecassoside round out the formula as skin-conditioning agents. CLERIVY describes the formula as a three-part cosmetic approach: early spot care, skin conditioning and targeted care for the look of post-blemish marks.

Once a blemish reaches the surface, the Hydrocolloid Pimple Patch covers the area. It contains less than 0.5% salicylic acid for cosmetic purposes. Salicylic acid is a beta hydroxy acid commonly used in exfoliating skincare. Phytosphingosine, a lipid naturally found in the skin, is included with panthenol and allantoin as skin-conditioning ingredients. The patch can stay in place for four to eight hours; if it turns opaque sooner, that is the visual cue to gently remove it.

Both products launching today are cosmetics, not drugs. All three patches are manufactured in South Korea: Y&K Biocos produces the Hydrocolloid Pimple Patch, while Raphas Co., Ltd. manufactures the Microdart Spot Patch and the upcoming OTC product. Raphas Co., Ltd. states that its Droplet Extension (DEN) process uses the formulation’s viscosity and air to form microneedles at room temperature.

Tested for Sensitive and Acne-Prone Skin

The Hydrocolloid Pimple Patch has completed human clinical testing at Cutis Biomedical Research Center Co., Ltd., where it was rated suitable for sensitive skin and non-comedogenic for acne-prone skin. In a one-week use test involving 22 participants with acne-prone skin, instrumental measurements recorded a statistically significant 14.5% decrease in a* values, an indicator of the look of redness (p<0.001). In a self-assessment survey, participants with sensitive skin rated overall usability 4.4 out of 5 on average, with all respondents reporting a positive experience.

Drug Facts Published Ahead of October Release

The upcoming Microdart Acne Patch is listed under OTC Monograph M006. Its Drug Facts label identifies salicylic acid 2% (2 g in 100 g) as the sole active ingredient and “Acne Treatment” as the purpose. Under “Uses,” the label states it is intended “for the treatment of acne” and that it “penetrates pores to eliminate most acne blemishes.”

Its 13 inactive ingredients include niacinamide, tranexamic acid and phytosphingosine HCl. The package lists 6% niacinamide, 3% tranexamic acid and 2% panthenol.

FDA listing records identify Guhada Co., Ltd. as the labeler and Raphas Co., Ltd. as the drug establishment. This listing does not constitute FDA approval or endorsement of the product.

Together, these three products make up CLERIVY’s initial U.S. patch lineup. The two cosmetic patches are now available on Amazon.com. The hydrocolloid patch is offered in 10 mm and 12 mm sizes in 30-, 72- and 96-count boxes. The cosmetic microdart patch comes in 6-, 12- and 18-patch kits, and the 18-patch kit includes 12 Blemish Clearing Pads. Four- and eight-patch packs are planned for the October OTC release.

Amazon serves as the brand’s first U.S. sales channel. After the October launch, CLERIVY plans to add serums and creams before expanding into other U.S. retail channels. More information is available at clerivy.com.

“CLERIVY is what happens when we extend our value chain all the way to the shelf. Kglowing’s data showed us the demand that no one was serving, and we built products to meet it,” said Yoon Jae-sub, CEO of Guhada. “With our recent selection for Global TIPS behind us, we intend to grow this first patch lineup — built on manufacturing technology proven in pharmaceuticals — into a leading brand in U.S. blemish care.”

About CLERIVY

CLERIVY is a Korean skincare brand operated by Guhada Co., Ltd. Its name connects “CLEAR” with “VALIDITY” through the letter “I,” which stands for both “Individual” and “Ingredients.” “CLEAR” represents the focus on what skin actually needs; “Individual” recognizes that those needs differ from person to person; and “Ingredients” promises thoughtfully selected elements, each chosen for a proven, well-defined purpose. “VALIDITY” is the brand’s commitment to documenting the basis for product claims and communicating that information clearly. Catch it early. Keep it covered. Visit clerivy.com to learn more.

About Guhada

Guhada Co., Ltd. is a South Korean cross-border commerce company. Through Kglowing, a global accelerator platform for K-brands, Guhada has supported the overseas expansion of approximately 30 K-beauty brands and now develops and operates its own brands, including CLERIVY.

Media Contact
CLERIVY (Guhada Co., Ltd.)
info@clerivy.com 

Required notices

CLERIVY MICRODART ACNE (salicylic acid 2%) is listed with the U.S. Food and Drug Administration as an over-the-counter monograph drug under OTC Monograph M006, Topical Acne Drug Products. The 4-patch and 8-patch packs carry NDC 87934-111-04 and NDC 87934-111-08, respectively. The marketing start date is August 11, 2026. The listing names Guhada Co., Ltd. as the labeler and Raphas Co., Ltd. (FEI 695914964) as the drug establishment. Its complete Drug Facts labeling is published by the U.S. National Library of Medicine under SPL Set ID 555e0963-025e-3731-e063-6394a90a679d at DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=555e0963-025e-3731-e063-6394a90a679d

Listing of a drug with FDA does not constitute FDA approval or endorsement of the product.

CLERIVY Hydrocolloid Pimple Patch and CLERIVY Microdart Spot Patch are cosmetic products and are not drugs. Both cosmetic packages state: “This product contains less than 0.5% Salicylic Acid for cosmetic purposes only. It is not intended to treat, prevent, or cure acne or any other medical condition.” Blemish Clearing Pads included with the Microdart Spot Patch are not intended for sanitizing or antiseptic use.

CLERIVY Microdart Acne Patch is scheduled for U.S. release in October 2026.

View original content to download multimedia:https://www.prnewswire.com/news-releases/clerivy-brings-a-k-beauty-take-on-pimple-patches-to-amazoncom-302858228.html

SOURCE CLERIVY

Continue Reading

Technology

“Shenzhen: Where the Future Takes Shape” Released to Mark the APEC Economic Leaders’ Meeting

Published

on

By

SHENZHEN, China, Nov. 16, 2026 /PRNewswire/ — On Nov. 15, as the 2026 APEC Economic Leaders’ Week got underway, host city Shenzhen released its promotional film “Shenzhen: Where the Future Takes Shape.”

Presented by the Publicity Department of the CPC Shenzhen Municipal Committee and produced by Shenzhen Media Group, the film takes shaping the future as its central theme. It showcases Shenzhen’s efforts to pilot new approaches and set an example for other cities, along with its progress in building a modern, people-centered city, through the lens of the APEC China 2026 theme, “Building an Asia-Pacific Community to Prosper Together.” It offers audiences across the Asia-Pacific and around the world a vivid look at Chinese modernization in practice.

A follow-up to “Gather in Shenzhen,” the film opens with the question “What will the future look like?” It explores what makes a city innovative, livable, beautiful, resilient, culturally advanced, and smart. Examples and data on the “Shenzhen cycle,” R&D investment, innovation clusters, government services, transport links at ports of entry, and the city’s ecology and culture show how Shenzhen is building a modern city.

Running just over six minutes, the film was shot in 8K ultra-high definition. Of the film’s more than 260 shots, 99% were newly filmed in 2026. The crew filmed across Shenzhen’s nine administrative districts, Dapeng New District, and the Shenzhen-Shanwei Special Cooperation Zone, with additional shoots in Hong Kong and Zhongshan. More than 300 residents appear on camera.

The film invites the world to gather in Shenzhen, witness the wonders, and build a better future together.

YouTube Link: https://www.youtube.com/watch?v=juktW8T6B1Q

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/shenzhen-where-the-future-takes-shape-released-to-mark-the-apec-economic-leaders-meeting-302939799.html

SOURCE Shenzhen Media Group

Continue Reading

Technology

TARSBOT and Aptiv Deepen Strategic Collaboration on Embodied AI

Published

on

By

SHANGHAI, Nov. 16, 2026 /PRNewswire/ — During the 9th China International Import Expo (CIIE), TARSBOT and Aptiv signed an agreement to further deepen their strategic collaboration in embodied AI.

Under the agreement, Aptiv expects to complete the deployment of 100-unit TARSBOT A-Series industrial embodied AI robots by the end of this year, covering 8 manufacturing process categories and 33 application scenarios, including flexible assembly, coordinated inspection and production management. The first batch of robots has already entered operation in real production-line environments at an Aptiv smart factory.

In addition, Aptiv products, including high-performance computing platforms, are intended to be introduced into TARSBOT embodied AI robots as a computing foundation to support highly reliable operation in real industrial settings. The parties plan to achieve mass production in 2026.

The two companies will also continue to validate applications in real industrial environments. Insights gained from production will support the iterative development of AWE (AI World Engine), TARSBOT’s general-purpose foundation model for embodied AI.

With the support of the Jiading District Government of Shanghai, TARSBOT and Aptiv have already been working closely to advance the development and scaled deployment of China’s first industrial embodied AI robot fleet with a target scale of 1,000 units. The first phase of the project is being implemented at an Aptiv production site, with the collaboration focused on adapting robots to real production processes and manufacturing requirements. The signing at CIIE marks a more systematic and scaled phase of the cooperation.

As the cooperation deepens, Aptiv’s high-performance computing platforms and intelligent power distribution solutions will be further integrated into TARSBOT embodied AI robots to support stable operation on real production lines. The high-performance computing platforms provide flexible and reliable compute for core robotic functions such as perception, decision-making and motion control. Combining TARSBOT’s end-to-end embodied AI capabilities and experience in real production-line applications with Aptiv’s established engineering expertise and rigorous standards, the collaboration aims to support efficient, reliable deployment at scale.

The collaboration aims to demonstrate that scalable deployment can be validated in practical industrial settings. As manufacturers worldwide face growing demand for intelligent automation and greater supply-chain efficiency, embodied AI is emerging as an important force in advancing next-generation productivity.

Looking ahead, TARSBOT and Aptiv will build on China’s rich real-world manufacturing environments to further connect robotic systems with operational applications. The collaboration aims to provide a validated and scalable industrial reference for replicating and expanding embodied AI across additional scenarios, creating broader opportunities for smart manufacturing worldwide.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/tarsbot-and-aptiv-deepen-strategic-collaboration-on-embodied-ai-302939162.html

SOURCE TARS

Continue Reading

Technology

Thunes Expands Real-Time Payouts to Bhutan, Unlocking the Nation’s Remittance Market

Published

on

By

Thunes’ Direct Global Network enables instant, 24/7 payments to all bank accounts in Bhutan, empowering Members to support the nation’s rapidly expanding remittance corridor.

SINGAPORE and THIMPHU, Bhutan, Nov. 16, 2026 /PRNewswire/ — Thunes, the Smart Superhighway to move money around the world, today announced the expansion of its Direct Global Network into the Kingdom of Bhutan, enabling its Network Members, including digital banks, money transfer operators (MTOs), and remittance service providers, to send real-time Consumer-to-Consumer (C2C) payouts to all licensed bank accounts in the country. 

The direct integration allows Non-Resident Bhutanese and expatriates across Australia, the Middle East, Southeast Asia, and North America to send funds home in Bhutanese Ngultrum (BTN) in seconds, avoiding multi-day clearing cycles and unpredictable intermediary markups. 

For Thunes’ Members, the new connection unlocks three key benefits:

Immediate market reach: Tap into the majority of Bhutan’s remittance volume by enabling person-to-person transfers.24/7 real-time deposits: Send funds to local bank accounts any time of day, eliminating batching delays.Higher payment success rates: Automated account verification and standardized sender data reduce failed transfers and return fees.

With over 70,000 Bhutanese nationals – nearly 10% of the population – living abroad, personal remittances account for 3% to 4% of national GDP and grew 69% from 2024 to 2025. Historically, these flows have relied on complex correspondent banking networks, incurring costs and delays.

With banks as the primary channel to send money home, Thunes clears these payments in seconds, supporting recurring salary transfers, personal savings, and family support for living expenses, healthcare, and education. Every transaction is backed by Thunes’ Fortress Compliance engine for strict AML and regulatory adherence, alongside its SmartX Treasury System for advanced liquidity management. 

Alex Young, Chief Network Officer at Thunes, said: “Bhutan represents a vital corridor where cross-border remittances serve as an indispensable financial lifeline for families. By connecting Bhutan’s entire banking sector directly into our Direct Global Network, we have established an effective, transparent way to ensure hard-earned funds arrive safely, securely, and in real time.”

Eugene Chua, Head of Network, APAC, at Thunes, added: “At Thunes, we are dismantling the friction that creates barriers to the global digital economy. Bhutan’s diaspora has grown significantly, especially across markets like Australia and Southeast Asia. Enabling instant consumer account deposits ensures expatriates have access to a reliable, transparent, and direct payment rail to send money back home.”

About Thunes:

For more information, visit: https://www.thunes.com/

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/thunes-expands-real-time-payouts-to-bhutan-unlocking-the-nations-remittance-market-302939104.html

Continue Reading

Trending